How much does quality matter? And how do you prioritise it when it actually costs more? This week HBI was at the IFC conference in Cape Town where there were strong views on the subject.
As we update our hospital reports on HBI Intelligence, it becomes increasingly clear that not all NHS systems are created equal. While some systems incentivise the private sector to muck in and help out, in others, private hospitals are seen as costly alternatives to the NHS run by avaricious groups. Take the following four diverse countries:
HBI reports this week that the number of licensed UK dentists in January 2022 was down 9.2% compared to the end of 2020. The government’s solution is, unsurprisingly, to encourage dentists from emerging markets to immigrate. However, this can sometimes leave the country of origin with a brain drain – and discourage investors who might otherwise buy a hospital group in that country.
Drawing inspiration from prediction lists that make the rounds this time of year like this one from our sources, we asked some of our team here at HBI to pen down some of their thoughts on what we can expect over the next 12 months and beyond. So here are our top picks for news and trends HBI expects will colour 2023 - across hospitals, labs, elderly care, fertility, dentistry, coronavirus, digitisation and more.
As 2022 comes to end, it seems appropriate to look back at some of the winners of the last year – and those who fared less well in a trying environment.
In an ideal world you wouldn’t have to pay for preventive care measures such as at-home tests, but with increasing pressure on healthcare services and in particular a lack of funding for preventative measures, increasing numbers of people are doing exactly that.
When a CEO steps down, journalists raise half an eyebrow. Is this a planned departure, in the works for months, with a readymade successor ready to step out of the wings? Or does it have a whiff of a hastily scrabbled jump (with, or without a push) suggesting possible malcontent, ill will, a clash of styles, or something else?
Why bother with telehealth? For all the huge sums raised, the high valuations and in some cases the spectacular IPOs, it's actually quite rare for them to make any money. Or latterly, for them to hold their share prices. Teladoc doubled its revenue, and Babylon quadrupled its revenue in 2021 - yet both have seen share prices drop 90% over the last two years. What gives?
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
